Understanding Hair Loss in Children 👧🏽🧒🏻👦 & treatments

Hair loss (alopecia) in children can be emotionally distressing for both the affected child and their caregivers. Unlike adult-pattern baldness, which is primarily genetic and hormonal, pediatric hair loss often stems from different underlying causes that are frequently treatable with proper medical intervention. This comprehensive guide examines the epidemiology, etiology, clinical presentation, diagnostic approaches, and current treatment options for the most common forms of pediatric hair loss.

Epidemiology of Pediatric Hair Loss

The prevalence of hair loss in the pediatric population varies by condition and geographic region. Approximately 3% of pediatric dermatology consultations involve hair disorders, with tinea capitis being most common in school-aged children (Castelo-Soccio, 2021). A multicenter study published in Pediatric Dermatology found that among children with hair loss, the distribution of causes was: tinea capitis (38%), alopecia areata (31%), telogen effluvium (12%), trichotillomania (8%), and traction alopecia (6%), with other causes accounting for the remaining 5% (Mirmirani et al., 2018).

Common Causes and Evidence-Based Treatments

1. Autoimmune-Related Hair Loss (Alopecia Areata)

Prevalence and Etiology: Alopecia areata (AA) affects approximately 2% of the general population at some point in their lifetime, with about 60% of patients experiencing their first episode before age 20 (Pratt et al., 2017). It is characterized by T-cell-mediated autoimmune attack on hair follicles in genetically predisposed individuals, with approximately 20% of patients having a positive family history.

Clinical Presentation:

• Well-circumscribed, smooth patches of hair loss without scaling or inflammation

• "Exclamation mark" hairs (tapered proximal hair shaft) at the periphery of lesions

• Positive hair pull test at the periphery of active lesions

• Nail changes (pitting, ridging) in 10-66% of patients

• Variants include:

  • Alopecia totalis (complete scalp hair loss)

  • Alopecia universalis (loss of all body hair)

  • Ophiasis pattern (band-like pattern of hair loss at the occipital and temporal margins)

Diagnosis:

• Primarily clinical

• Dermoscopy showing yellow dots, black dots, broken hairs, and exclamation mark hairs

• Scalp biopsy (rarely needed) shows peribulbar lymphocytic infiltration ("swarm of bees")

Treatment: Treatment options have significantly expanded in recent years based on evidence from randomized controlled trials (Price et al., 2022):

For limited AA (<50% scalp involvement):

• High-potency topical corticosteroids (Class I or II) under occlusion

• Intralesional corticosteroids: triamcinolone acetonide (5-10mg/ml) every 4-6 weeks

• Minoxidil 5% solution twice daily (adjunctive therapy)

For extensive AA (>50% scalp involvement) or rapidly progressive disease:

• Systemic pulse corticosteroids for acute, rapidly progressive disease

• JAK inhibitors: Recent FDA approval of baricitinib (2022) and ritlecitinib (2023) for severe AA

• Off-label use of tofacitinib showing 70-90% hair regrowth in pediatric patients with severe AA (Putterman et al., 2020)

• Contact immunotherapy with diphenylcyclopropenone (DPCP)

• Methotrexate with or without low-dose prednisolone for recalcitrant cases

Emerging therapies:

• IL-23/IL-17 antagonists showing promise in early trials

• Platelet-rich plasma injections

• JAK inhibitor-containing topical formulations

2. Scalp Fungal Infections (Tinea Capitis)

Prevalence and Etiology: Tinea capitis remains the most common cause of hair loss in prepubertal children, particularly affecting those aged 3-7 years. The condition is caused by dermatophyte fungi, predominantly Trichophyton tonsurans in North America and Europe (accounting for 50-90% of cases), and Microsporum canis in parts of Asia, Southern Europe, and Africa (Ginter-Hanselmayer et al., 2020).

Clinical Presentation:

• Round or oval patches of hair loss with broken hairs

• Black dots (broken hair shafts) visible on the scalp

• Scaling, erythema, and sometimes pustules

• Potential for kerion formation (inflammatory, boggy, purulent mass)

• Possible cervical and occipital lymphadenopathy

Diagnosis:

• Direct microscopy (KOH preparation)

• Fungal culture (gold standard)

• Wood's lamp examination (helpful for M. canis which fluoresces bright green)

• Dermoscopy showing comma hairs, corkscrew hairs, and black dots

Treatment: According to the most recent guidelines from the American Academy of Dermatology (Eichenfield et al., 2021):

• Oral antifungal therapy is mandatory, as topical treatment alone is ineffective

• First-line treatment: Oral terbinafine for 4-6 weeks (weight-based dosing: 10-20kg: 62.5mg/day; 20-40kg: 125mg/day; >40kg: 250mg/day)

• Alternative: Griseofulvin (ultramicrosize) 10-15mg/kg/day for 6-12 weeks

• Adjunctive therapy with antifungal shampoos containing ketoconazole 2% or selenium sulfide 2.5%

• Family members should be screened and preventive measures implemented

• Follow-up with repeat fungal culture to confirm mycological cure

Recent studies have shown oral terbinafine has superior efficacy compared to griseofulvin for T. tonsurans infections, with clinical cure rates of 95% versus 79% respectively (Chen et al., 2022).

3. Tension-Related Hair Loss (Traction Alopecia)

Prevalence and Etiology: Traction alopecia results from chronic tension on hair follicles due to hairstyling practices. It affects approximately 17-18% of African American schoolgirls and is increasingly seen in other populations with the popularity of tight hairstyles (Akingbola & Vyas, 2023).

Clinical Presentation:

• Hair loss along the frontotemporal hairline, vertex, or occipital region

• Initial presentation may include perifollicular erythema and pustules

• Progressive thinning with recession of the frontal and temporal hairline

• If chronic, can progress to scarring and permanent hair loss

Diagnosis:

• Clinical history and examination

• Dermoscopy showing reduced hair density, broken hairs, and peripilar casts

• Biopsy in late stages may show follicular scarring

Treatment:

• Primary intervention is cessation of traumatic hairstyling practices

• Education about protective hairstyling techniques

• Topical minoxidil 5% to stimulate regrowth in non-scarring areas

• Anti-inflammatory treatments: topical steroids for acute inflammation

• Hair transplantation may be considered for permanent scarring alopeciaHair-Pulling Behaviors (Trichotillomania)

Prevalence and Etiology: Trichotillomania is classified as an obsessive-compulsive related disorder in DSM-5, affecting 1-2% of pediatric and adolescent populations, with a female predominance (2:1) (Grant & Chamberlain, 2020). Onset typically occurs between ages 9-13, often triggered by psychological stressors.

Clinical Presentation:

• Bizarre, irregular pattern of incomplete hair loss

• Hairs of varying lengths in affected areas

• Sparing of difficult-to-reach areas

• Absence of scalp inflammation

• Associated findings may include trichophagia (hair eating), which can lead to trichobezoars

Diagnosis:

• Clinical assessment

• Dermoscopy showing broken hairs of varying lengths, absence of exclamation mark hairs

• Biopsy (rarely needed) shows increased catagen/telogen hairs, empty follicles, and trichomalacia

Treatment: Based on systematic reviews and meta-analyses (McGuire et al., 2022):

• Cognitive behavioral therapy (CBT) is first-line treatment with 60-80% response rates

• Habit reversal training (HRT) and acceptance and commitment therapy (ACT)

• N-acetylcysteine (1200-2400mg daily) demonstrated efficacy in pediatric randomized controlled trials

• Selective serotonin reuptake inhibitors (SSRIs) for comorbid anxiety/depression

• Olanzapine or aripiprazole for treatment-resistant cases

• Family therapy and support groups

4. Telogen Effluvium

Prevalence and Etiology: Telogen effluvium (TE) is characterized by excessive shedding of telogen hairs following a triggering event that disrupts the normal hair cycle. In children, common triggers include:

• Febrile illnesses and infections (including COVID-19)

• Major surgery or trauma

• Medications (especially anticonvulsants)

• Nutritional deficiencies (iron, zinc, biotin)

• Psychological stress

• Endocrine disorders (thyroid dysfunction)

Clinical Presentation:

• Diffuse thinning rather than discrete patches

• Increased daily hair shedding (>100 hairs/day)

• Positive hair pull test (>10% telogen hairs)

• Typically occurs 2-3 months after the triggering event

• No scalp inflammation or scarring

Diagnosis:

• Detailed history to identify triggers

• Laboratory tests to rule out nutritional deficiencies or endocrine abnormalities

• Hair pull test and trichogram

• Dermoscopy showing empty follicles and regrowing hairs

Treatment:

• Addressing the underlying cause

• Nutritional supplementation if deficiencies are identified

• Reassurance about the self-limiting nature (typically resolves within 6-12 months)

• Minoxidil 2% may accelerate recovery in cases lasting >6 months

5. Hair-Pulling Behaviors (Trichotillomania)

Prevalence and Etiology: Trichotillomania is classified as an obsessive-compulsive related disorder in DSM-5, affecting 1-2% of pediatric and adolescent populations, with a female predominance (2:1) (Grant & Chamberlain, 2020). Onset typically occurs between ages 9-13, often triggered by psychological stressors.

Clinical Presentation:

• Bizarre, irregular pattern of incomplete hair loss

• Hairs of varying lengths in affected areas

• Sparing of difficult-to-reach areas

• Absence of scalp inflammation

• Associated findings may include trichophagia (hair eating), which can lead to trichobezoars

Diagnosis:

• Clinical assessment

• Dermoscopy showing broken hairs of varying lengths, absence of exclamation mark hairs

• Biopsy (rarely needed) shows increased catagen/telogen hairs, empty follicles, and trichomalacia

Treatment: Based on systematic reviews and meta-analyses (McGuire et al., 2022):

• Cognitive behavioral therapy (CBT) is first-line treatment with 60-80% response rates

• Habit reversal training (HRT) and acceptance and commitment therapy (ACT)

• N-acetylcysteine (1200-2400mg daily) demonstrated efficacy in pediatric randomized controlled trials

• Selective serotonin reuptake inhibitors (SSRIs) for comorbid anxiety/depression

• Olanzapine or aripiprazole for treatment-resistant cases

• Family therapy and support groupsDiagnostic Approach for Pediatric Hair Loss

A systematic approach to diagnosis includes:

1. Detailed History:

   • Onset and progression of hair loss

   • Family history of hair disorders

   • Recent illnesses, medications, or stressors

   • Hair care practices and styling techniques

2. Physical Examination:

   • Pattern and distribution of hair loss

   • Scalp signs (inflammation, scaling, pustules)

   • Hair shaft examination

   • Associated findings (nail changes, lymphadenopathy)

3. Diagnostic Tests:

   • Hair pull test

   • Dermoscopy (trichoscopy)

   • KOH preparation and fungal culture

   • Nutritional and hormonal screening

   • Scalp biopsy in unclear cases

Psychological Impact and Support

Hair loss can significantly impact a child's quality of life, self-esteem, and social functioning. A study by Christensen et al. (2017) found that children with alopecia had higher rates of anxiety and depression compared to their peers. Comprehensive management should include:

• Age-appropriate counseling

• School intervention to prevent bullying

• Support groups such as the National Alopecia Areata Foundation

• Cosmetic approaches (hats, scarves, wigs) for severe cases

• Regular assessment of psychological well-being

Conclusion

Pediatric hair loss is often treatable with timely diagnosis and appropriate intervention. The prognosis varies by condition, with tinea capitis and telogen effluvium typically resolving completely, while alopecia areata may have a relapsing-remitting course. Traction alopecia can be reversed if caught early, but may lead to permanent loss if scarring occurs.

When evaluating a child with hair loss, a multidisciplinary approach involving dermatologists, pediatricians, and when needed, mental health professionals, ensures comprehensive care addressing both the physical and psychological aspects of these conditions.

References

Akingbola, C. O., & Vyas, J. (2023). Traction alopecia: A neglected entity in pediatric care. Pediatric Dermatology, 40(1), 112-118.

Castelo-Soccio, L. (2021). Diagnosis and management of alopecia in children. Pediatric Clinics of North America, 68(2), 345-362.

Chen, X., Li, L., Gao, L., Wang, L., & Chen, H. (2022). A randomized, double-blind comparative study of oral terbinafine versus griseofulvin in children with tinea capitis. Journal of the American Academy of Dermatology, 86(4), 801-808.

Christensen, T., Yang, J. S., & Castelo-Soccio, L. (2017). Bullying and quality of life in pediatric alopecia areata. JAMA Dermatology, 153(12), 1307-1308.

Eichenfield, L. F., Friedlander, S. F., Leyden, J., & Pickering, B. (2021). Practical recommendations for the treatment of tinea capitis in children. Pediatrics, 147(4), e2020031096.

Ginter-Hanselmayer, G., Nenoff, P., & Kurrat, W. (2020). Epidemiology of tinea capitis in Europe: Current state and changing patterns. Mycoses, 63(8), 785-792.

Grant, J. E., & Chamberlain, S. R. (2020). Trichotillomania and skin picking disorder: Different kinds of OCD. American Journal of Psychiatry, 177(2), 112-123.

McGuire, J. F., Kugler, B. B., Park, J. M., Horng, B., Lewin, A. B., Murphy, T. K., & Storch, E. A. (2022). Evidence-based assessment and intervention for trichotillomania in children and adolescents. Current Psychiatry Reports, 24(1), 1-13.

Mirmirani, P., Samimi, S. S., Mostow, E., & Mathes, E. (2018). Multicenter study of pediatric alopecia patterns: A retrospective review of 716 patients. Pediatric Dermatology, 35(6), 806-811.

Pratt, C. H., King, L. E., Messenger, A. G., Christiano, A. M., & Sundberg, J. P. (2017). Alopecia areata. Nature Reviews Disease Primers, 3, 17011.

Price, V. H., Hordinsky, M. K., Olsen, E. A., Roberts, J. L., Siegfried, E. C., & Hantash, B. (2022). Alopecia areata: Guidelines of care for the management of alopecia areata. Journal of the American Academy of Dermatology, 86(6), 1217-1232.

Putterman, E., Castelo-Soccio, L., Farhadian, J. A., Juhasz, M., Mesinkovska, N., Motosko, C., & Shapiro, J. (2020). JAK inhibitor therapy in pediatric patients with alopecia areata. Journal of the American Academy of Dermatology, 83(6), 1710-1713.

©2025 Hairline Illusions™

#hairlineillusions #tractionalopecia #kidshairloss #hairpulling #TineaCapitis #TelogenEffluvium